The Genetic Basis of Congenital Heart Disease in Africa
NCT01952171
Cardiovascular Abnormalities, Cardiovascular Diseases
Washington D.C., District of Columbia, United States
View Trial DetailsNCT Number: NCT01665261
The purpose of this study is to test the accuracy of 7 indicators in screening congenital heart defects (CHD) in all newborns (symptomatic or asymptomatic) to determine whether these indicators could be applied in the nationwide newborn CHD screening. The investigator's hypothesis is that 7 indicators are effective in neonate CHD screening with the acceptable accuracy.
Looking for future studies?
Notify Me6 hour–72 hour
All sexes
Observational
Songjiang District Central Hospital, Shanghai, Shanghai Municipality, China
Congenital heart defects (CHD) are among the most common major congenital anomalies, and they occur worldwide with an incidence of about 8-12/1,000 live births , Most of these defects are mild or moderate. They either do not need treatment or treatment is needed only after infancy. Other defects are severe and require early treatment in infancy, which are the primary objectives of screening, because they are at risk of adverse or irreversible outcomes as a consequence of congenital heart defects. However, about half the neonates in the nursery have no distinctive clinical signs (symptoms, abnormal murmurs or cyanosis).So it's necessary to develop a screening strategy for neonatologist and pediatrician, especially physicians in community. Screening strategy in our study consists of 7 indicators: Family history of CHD, tachypnea, heart murmurs(≥ 2 grade), cyanosis, other non-cardiac malformations,special face feature(relating to chromosomal or non-chromosomal syndromes), subnormal Pulse Oximetry reading (Oxygen saturation of less than 95% in either limb or more than 3% difference)。The newborn babies with any of these 7 indicators positive will be considered positive-screened and echocardiography will performed.
The whole study (screening for CHDs with 7 indicators and performing the echocardiography for diagnosis) will be conducted by one single investigator (Quming Zhao from Children's Hospital of Fudan University). The new generation Pulse Oximetry has been proved to have low intraobserver and interobserver variability, but the interobserver variability in clinical evaluation (especially murmurs and cyanosis) remain unknown, the investigator will also assess the interobserver variability by comparing Quming Zhao and other two pediatricians (from the participating Hospital)(blind to each other).
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: The goldstandard for CHD diagnosis is the echocardiography performed within 1 hour from the screening completed.
Sensitivity, specificity, negative and positive predictive value, negative and positive likelihood ratio of 7 indicators for the detection of all CHDs and major CHDs as gold standard the echocardiography.
Children's Hospital of Fudan University
Other
Accuracy Assessment of 7 Clinical Indicators in Newborn Screening for Congenital Heart Disease
Acronym: NSCHD
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT01952171
Cardiovascular Abnormalities, Cardiovascular Diseases
Washington D.C., District of Columbia, United States
View Trial DetailsNCT05902013
Airway Complication of Anesthesia, Cardiovascular Abnormalities
Vienna, State of Vienna, Austria
View Trial DetailsNCT06650787
Cardiovascular Abnormalities, Cardiovascular Diseases
Shanghai, Shanghai Municipality, China
View Trial DetailsNCT05524324
Cardiovascular Abnormalities, Cardiovascular Diseases
Caen, France
View Trial Details